Home ›
Trademark Categories ›
Pharmaceuticals ›
2014 ›
NO ›
NOCUVANT
Trademark search for:
NOCUVANT
No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.
Trademark records may change over time.
For the most up-to-date trademark status, domain availability,
and social handle checks, run a live search.
Check latest trademark, domains & social handles
Live search · Most up-to-date results
USPTO Filing History
Key events recorded for this trademark application
2021-02-09 — Application filed
2021-02-12 — Application filed
2021-05-13 — Application filed
2021-08-31 — Assigned to examiner
2021-09-02 — Approved for pub - principal register
2021-09-15 — Notification of notice of publication e-mailed
2021-10-05 — Published for opposition
2021-10-05 — Official gazette publication confirmation e-mailed
2021-11-04 — Extension of time to oppose received
2022-02-13 — Extension of time to oppose process - terminated
2022-03-29 — Noa e-mailed - sou required from applicant
2022-07-08 — Attorney/dom.rep.revoked and/or appointed
2022-07-08 — Teas change of owner address received
2022-07-08 — Teas change of correspondence received
2022-07-08 — Applicant/correspondence changes (non-responsive) entered
2022-07-08 — Teas revoke/app/change addr of atty/dom rep received
2022-09-01 — Sou teas extension received
2022-09-01 — Sou extension 1 filed
2022-09-01 — Sou extension 1 granted
2022-09-03 — Notice of approval of extension request e-mailed
2023-05-01 — Application abandoned
2023-05-01 — Application abandoned
2023-05-01 — Final status recorded
Owner Information
Serenity Pharmaceuticals LLC
Mississauga, Ontario CA
Serenity Pharmaceuticals LLC
Miami , FL
Correspondent
Jessica L. Rothstein Goodwin Procter LLP 620 Eighth Avenue New York, NY 10018 UNITED STATES
Filing Details
Filing Date:
2021-02-09
Status Date:
2023-05-01
Disclaimer: This page is informational only and does not constitute legal advice.
Trademark availability depends on jurisdiction, usage, and legal interpretation.